Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+proteins

30 Results

Sort By:

Improved Gene Therapy to Enhance mRNA Expression

Unmet Need / Invention Novelty: Haploinsufficiency occurs when one gene allele is inactivated and the amount of gene product expressed from the remaining active allele is insufficient for proper gene function. Targeted restoration of mRNA expression and translation may offer a therapeutic window. Technical Details: Johns Hopkins researchers designed...

Published: 5/13/2024 | Inventor(s): Jeffery Coller, Bahareh Torkzaban

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins

Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same

Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...

Published: 5/10/2024 | Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng

Keywords(s):

The Efficacy of Nanozyme in Neurodegenerative Diseases

Unmet NeedOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure. Technology OverviewDisclosed herein are novel...

Published: 5/10/2024 | Inventor(s): Xiaobo Mao, Shuya Li, Weiwei He

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Technology Classifications > Therapeutic Modalities > Proteins

Transgenic Fungi that Kill Malaria Parasites in Mosquitoes

Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...

Published: 5/9/2024 | Inventor(s): Raymond St. Leger, Angray Kang, Weiguo Fang, Marcelo Jacobs-Lorena

Keywords(s): Biologics, Disease Indication, Disease Management System, Healthcare Management, Infectious Diseases, Malaria, Operations Management, Parasitic Infections, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Computers, Electronics & Software > Clinical Management, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Computers, Electronics & Software, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections

Identification of TDP-43 Cryptic Exons as Functional Fluid Biomarkers for Alzheimer's Disease and Related Dementia

JHU C16735Unmet Need: TDP-43 (Tar DNA-binding protein 43) acts as a guardian of the transcriptome by repressing the splicing of non-conserved, unannotated cryptic exons. Loss of TDP-43 function causes neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Limbic-Predominant Age-Related TDP-43 Encephalopathy...

Published: 5/13/2024 | Inventor(s): Philip Wong, Jonathan Ling

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Proteins, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Dementia

Mutant Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH): A Novel Anticancer Therapeutic for Solid Malignancies

Unmet Need: One of the hallmarks of cancer cells is metabolic reprogramming for faster metabolism and cell growth. For example, increased glycolysis has long been known to be part of cancer cells’ biochemical adaptation. One of the key enzymes of glycolysis is glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which catalyzes the first step of energy...

Published: 5/9/2024 | Inventor(s): Shanmugasundaram Ganapathy-Kanniappan

Keywords(s): Biologics, Cancers, Disease Indication, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Optimized Biliary Hydrodynamic Injection via Endoscopic Retrograde Cholangiopancreatography for Macromolecule Delivery into the Liver

Unmet NeedThe liver is a critical organ that performs more than 500 physiological functions in the human body including maintenance of metabolic homeostasis, digestion of drugs & hormones, and secretion of essential proteins. Unfortunately, the liver is susceptible to a wide variety of diseases that generally result from viral infection, inheritance...

Published: 5/10/2024 | Inventor(s): Vivek Kumbhari, Robert Kruse, Yuting Huang, Florin Selaru

Keywords(s):

Category(s): Clinical and Disease Specializations > Hepatology, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins

Use of CFTR Modulators for the Treatment of ADPKD

Unmet Need: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the progressive enlargement of multiple renal cysts, leading to chronic pain, hypertension, and decline in renal function and renal failure in a substantial subset of patients. Fluid enters the cysts via a cAMP-dependent process involving the cystic fibrosis transmembrane...

Published: 5/9/2024 | Inventor(s): Liudmila Cebotaru

Keywords(s): Biologics, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Multi-epitope Fusion Antigen Vaccine for ETEC

Unmet Need: Enterotoxigenic Escherichia coli (ETEC) is the leading cause of diarrheal diseases worldwide but to date no effective vaccine exists due to the heterogeneity in ETEC strains. There is a need for a vaccine that elicits a broad yet productive immune response against multiple ETEC antigens to provide protection. Technical Details: Researchers...

Published: 5/9/2024 | Inventor(s): Weiping Zhang, David Sack

Keywords(s): Biologics, Disease Indication, Drug Delivery Mechanism, Immunotherapy, Infectious Diseases, Oral Administration, Protein, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Human Serum Albumin-PSA proaerolysin Prodrug

UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...

Published: 5/9/2024 | Inventor(s): John Isaacs, Samuel Denmeade, William Brennen

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

1 2 3